Hepatitis C and diabetes: One treatment for two diseases?

Liver International

Volumn 30, Issue 3, 2010, Pages 356-364

  Pattullo, Venessa ^a,b   Heathcote, Jenny ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b University of Sydney   (Australia)

Author keywords

Diabetes; Hepatitis C; Hepatocellular carcinoma; Insulin resistance; Liver transplant; Metabolic syndrome; Pegylated interferon; Ribavirin; Sustained virological response

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; INTERFERON; METFORMIN; PEGINTERFERON; PIOGLITAZONE; RIBAVIRIN;

ANTIVIRAL THERAPY; CANCER INCIDENCE; CHRONIC LIVER DISEASE; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VIRUS CELL INTERACTION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLUCOSE TOLERANCE TEST; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER NEOPLASMS; METABOLIC SYNDROME X;

EID: 77950600860     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02185.x     Document Type: Review

References (82)

1. Hepatitis C - global prevalence. Wkly Epidemiol Rec 1999, 74:425-7. World Health Organization
2. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000, 132:296-305.
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002, 36:S35-46.
4. Vogt M, Lang T, Frosner G. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999, 341:866-70.
5. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994, 21:1135-9.
6. Grimbert S, Valensi P, Levy-Marchal C. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol 1996, 20:544-8.
7. Caronia S, Taylor K, Pagliaro L. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999, 30:1059-63.
8. Mason AL, Lau JY, Hoang N. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999, 29:328-33.
9. Hui JM, Sud A, Farrell GC. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003, 125:1695-704.
10. Romero-Gomez M, Del Mar Viloria M, Andrade RJ. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-41.
11. Moucari R, Asselah T, Cazals-Hatem D. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008, 134:416-23.
12. Konishi I, Horiike N, Hiasa Y. Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Hepatol Res 2007, 37:331-6.
13. Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci 2009, doi, 10.1029/2007GB003166
14. Kita Y, Mizukoshi E, Takamura T. Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Metabolism 2007, 56:1682-8.
15. Petta S, Camma C, Di Marco V. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008, 103:1136-44.
16. Veldt BJ, Chen W, Heathcote EJ. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008, 47:1856-62.
17. Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev 2009, 18:2054-60.
18. Konishi I, Hiasa Y, Shigematsu S. Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus. Liver Int 2009, 29:1194-201.
19. Baid S, Cosimi AB, Farrell ML. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001, 72:1066-72.
20. John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002, 8:708-13.
21. Veldt BJ, Poterucha JJ, Watt KD. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009, 9:1406-13.
22. Bigam DL, Pennington JJ, Carpentier A. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000, 32:87-90.
23. Kruszynska YT, Harry DS, Bergman RN, McIntyre N. Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients. Diabetologia 1993, 36:121-8.
24. Mehta SH, Brancati FL, Strathdee SA. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003, 38:50-6.
25. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996, 19:998-1000.
26. Okan V, Araz M, Aktaran S. Increased frequency of HCV but not HBV infection in type 2 diabetic patients in Turkey. Int J Clin Pract 2002, 56:175-7.
27. Sangiorgio L, Attardo T, Gangemi R. Increased frequency of HCV and HBV infection in type 2 diabetic patients. Diabetes Res Clin Pract 2000, 48:147-51.
28. Huang JF, Dai CY, Hwang SJ. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol 2007, 102:1237-43.
29. Shintani Y, Fujie H, Miyoshi H. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-8.
30. Pazienza V, Clement S, Pugnale P. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007, 45:1164-71.
31. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001, 98:9599-604.
32. Lecube A, Hernandez C, Genesca J, Simo R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care 2006, 29:1096-101.
33. Walsh MJ, Jonsson JR, Richardson MM. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55:529-35.
34. Emanuelli B, Peraldi P, Filloux C. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001, 276:47944-9.
35. Cua IH, Hui JM, Bandara P. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007, 46:66-73.
36. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int 2009, 29((Suppl. 2)):13-25.
37. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-97. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
38. Grigorescu M, Radu C, Cri Scedil An D. Metabolic syndrome, insulin resistance and adiponectin level in patients with chronic hepatitis C. J Gastrointestin Liver Dis 2008, 17:147-54.
39. Chen W, Wong T, Tomlinson G, Krahn M, Heathcote EJ. Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic. J Hepatol 2008, 49:711-7.
40. Meigs JB, Wilson PW, Fox CS. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006, 91:2906-12.
41. Soliman W, Kuczynski M, Fantus IG, Heathcote J. The prevalence of insulin resistance in patients with chronic hepatitis C and B (abstract). Gastroenterology 2008, 134:M1771.
42. Montano-Loza AJ, Sultan A, Falanga D, Loss G, Mason AL. Immunogenetic susceptibility to diabetes mellitus in patients with liver disease. Liver Int 2009, 29:1543-51.
43. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-9.
44. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-53.
45. Radikova Z, Koska J, Huckova M. Insulin sensitivity indices: a proposal of cut-off points for simple identification of insulin-resistant subjects. Exp Clin Endocrinol Diabetes 2006, 114:249-56.
46. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006, 29((Suppl. 1)):S43-8. Expert Committee on the Diagnosis and Classification of Diabetes
47. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26((Suppl. 1)):S5-20. Expert Committee on the Diagnosis and Classification of Diabetes
48. Huang JF, Yu ML, Dai CY. Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection. Am J Gastroenterol 2008, 103:1933-40.
49. Tuomilehto J, Lindstrom J, Eriksson JG. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-50.
50. Aytaman A, McFarlane SI. Uncovering glucose abnormalities in people with hepatitis C infection: should oral glucose tolerance test become a standard of care? Am J Gastroenterol 2008, 103:1941-3.
51. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994, 19:616-27.
52. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003, 39:1049-55.
53. Saito K, Inoue S, Saito T. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 2002, 51:100-4.
54. Ohata K, Hamasaki K, Toriyama K. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97:3036-43.
55. Saliba F, Lakehal M, Pageaux GP. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007, 13:136-44.
56. Sanchez-Perez B, Aranda Narvaez JM, Santoyo Santoyo J. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients. Transplant Proc 2008, 40:2994-6.
57. Thuluvath PJ. Is there a link between hepatitis C virus and new onset of diabetes mellitus after liver transplantation? Liver Transpl 2007, 13:5-7.
58. Chen T, Jia H, Li J. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl Int 2009, 22:408-15.
59. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003, 38:639-44.
60. Ohki T, Tateishi R, Sato T. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008, 6:459-64.
61. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002, 35:105-9.
62. Dick AA, Spitzer AL, Seifert CF. Liver transplantation at the extremes of the body mass index. Liver Transpl 2009, 15:968-77.
63. Hanouneh IA, Feldstein AE, McCullough AJ. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008, 14:1287-93.
64. Guiltinan AM, Kaidarova Z, Custer B. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008, 167:743-50.
65. Ishizaka N, Ishizaka Y, Takahashi E. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002, 359:133-5.
66. Ishizaka Y, Ishizaka N, Takahashi E. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 2003, 67:26-30.
67. Laryea M, Watt KD, Molinari M. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007, 13:1109-14.
68. Romero-Gomez M, Diago M, Andrade RJ. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009, 50:1702-8.
69. Elgouhari HM, Cesario KB, Lopez R, Zein NN. Pioglitazone improves early virologic kinetic response to Peg IFN/RBV combination therapy in hepatitis C genotype 1 naïve pts. Hepatology 2008, 48:383A.
70. Conjeevaram HS, Burant CF, McKenna B. A randomized, double-blind, placebo-controlled study of PPAR-gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology 2008, 48:384A.
71. Hickman IJ, Clouston AD, Macdonald GA. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002, 51:89-94.
72. Hickman IJ, Jonsson JR, Prins JB. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004, 53:413-9.
73. Kawaguchi T, Ide T, Taniguchi E. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007, 102:570-6.
74. Chehadeh W, Al-Nakib W. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy. J Med Virol 2009, 81:610-8.
75. Chehadeh W, Abdella N, Ben-Nakhi A, Al-Arouj M, Al-Nakib W. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol 2009, 24:42-8.
76. Simo R, Lecube A, Genesca J, Esteban JI, Hernandez C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006, 29:2462-6.
77. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008, 48:721-7.
78. Arase Y, Suzuki F, Suzuki Y. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009, 49:739-44.
79. Giordanino C, Bugianesi E, Smedile A. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol 2008, 103:2481-7.
80. Veldt BJ, Poterucha JJ, Watt KD. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008, 8:2426-33.
81. Carrion JA, Martinez-Bauer E, Crespo G. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009, 50:719-8.
82. Hanouneh IA, Feldstein AE, Lopez R. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2008, 6:584-9.